MHRA approves Mounjaro for diabetes and weight management
Betsy Goodfellow | January 26, 2024 | News story | Medical Communications | Diabetes, MHRA, Mounjaro, weight management
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it has approved a four-dose version of the diabetes and weight management medicine Mounjara (tirzepatide) in the form of Mounjaro KwikPen.
The four-dose version is intended to cover a month’s treatment and is approved to treat adult patients with type 2 diabetes and for weight management in adults with a BMI of 30kg/m2 or more (obesity), or those with a BMI between 27-30kg/m2 (overweight) who have weight-related health problems including prediabetes, high blood pressure, high cholesterol or heart issues.
The drug is intended to be used in combination with a reduced calorie diet and increased physical activity.
Julian Beach MHRA interim executive director, Healthcare Quality and Access, commented: “The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people’s health, is clear. This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month’s treatment, of one dose per week.”
Douglas Twenefour, head of care at Diabetes UK, added: “We hope the MHRA’s approval of this device will help people living with type 2 diabetes, who are eligible, to access this effective treatment. Supporting people with type 2 diabetes to lose weight and manage their blood sugar levels is key to reducing the risk of diabetes-related complications, and tirzepatide (Mounjaro) expands the range of treatment options available to help people achieve this.”
Betsy Goodfellow
Related Content
Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …
IMed Consultancy releases white paper on Digital Mental Health Technologies
IMed Consultancy, a consultancy and service provider for the medical and health technology sector, has …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
